Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Aug 30;11:712807. doi: 10.3389/fonc.2021.712807

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Hirani, Gauthier, Allen, Wight and Pearce

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

A depiction of the inflammatory milieu of versican V0/V1 and versikine and their respective effects on tumour immunity. V0/V1 presence leads to the stimulation of immune-suppressive cytokines within the TME, leading to a pro-tumourigenic environment with polarisation of immune cells to TAMs and regulatory T cells. The breakdown of V1 by versicanases such as ADAMTS1 leads to an adaptive immunity against the tumour with recruitment of CD8+ T cells and polarisation of monocytes towards M1 macrophages. ADAMTS1, ADAM Metallopeptidase with Thrombospondin Type 1 Motif 1; TAM, Tumour-associated macrophage.